Antihypertensive and vasorelaxant effects of aqueous extract of *Artemisia campestris* L. from Eastern Morocco

Ikram Dib, Monique Tits, Luc Angenot, Jean Noel Wauters, Asmae Assaidi, Hassane Mekhfî, Mohammed Aziz, Mohammed Bnouham, Abdelkhaleq Legssyer, Michel Frederich, Abderrahim Ziyyat

PII: S0378-8741(17)30339-2
DOI: http://dx.doi.org/10.1016/j.jep.2017.05.036
Reference: JEP10877

To appear in: *Journal of Ethnopharmacology*

Received date: 25 January 2017
Revised date: 5 May 2017
Accepted date: 30 May 2017

Cite this article as: Ikram Dib, Monique Tits, Luc Angenot, Jean Noel Wauters, Asmae Assaidi, Hassane Mekhfî, Mohammed Aziz, Mohammed Bnouham Abdelkhaleq Legssyer, Michel Frederich and Abderrahim Ziyyat Antihypertensive and vasorelaxant effects of aqueous extract of *Artemisia campestris* L. from Eastern Morocco, *Journal of Ethnopharmacology* http://dx.doi.org/10.1016/j.jep.2017.05.036

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Antihypertensive and vasorelaxant effects of aqueous extract of *Artemisia campestris* L. from Eastern Morocco

Ikram Dib\textsuperscript{a1}, Monique Tits\textsuperscript{b2}, Luc Angenot\textsuperscript{b}, Jean Noel Wauters\textsuperscript{b3}, Asmae Assaidi\textsuperscript{a4}, Hassane Mekhfi\textsuperscript{a5}, Mohammed Aziz\textsuperscript{a}, Mohammed Bnouham\textsuperscript{a}, Abdelkhaleq Legssyer\textsuperscript{a}, Michel Frederich\textsuperscript{b6}, Abderrahim Ziyyat\textsuperscript{a*}

\textsuperscript{a} Laboratoire de Physiologie, Génétique et Ethnopharmacologie URAC-40, Département de Biologie, Faculté des Sciences, Université Mohammed Premier, Oujda-Maroc.

\textsuperscript{b} Laboratoire de Pharmacognosie, Centre Interfacultaire de Recherche sur les Médicaments (CIRM), Université de Liège, Belgique

ikram187@live.fr
m.tits@ulg.ac.be
l.angenot@ulg.ac.be
jean-noel.wauters@ulg.ac.be
assaidi.asmae@yahoo.fr
hmekhfi@yahoo.fr
azizmo5@yahoo.fr
mbnouham@yahoo.fr
a.legssyer@ump.ac.ma
m.frederich@ulg.ac.be

\textsuperscript{1} +212 (0)6 78 19 07 50
\textsuperscript{2} +32 (0)43 66 43 34
\textsuperscript{3} +32 (0)43 66 43 35
\textsuperscript{4} +212 (0)6 16 19 74 54
\textsuperscript{5} +212 (0)5 36 50 90 77 (N° tel de laboratoire)
\textsuperscript{6} +32 (0)43 66 43 31
Abstract

*Correspondence to: Pr Abderrahim ZIYYAT Laboratoire de Physiologie, Génétique et Ethnopharmacologie, Département de Biologie, Faculté des Sciences, Université Mohamed Premier, Oujda – Maroc. Tel.: +(212) 6 67 08 61 22.

**Ethnopharmacological relevance:**

*Artemisia campestris* L. (Asteraceae) has many traditional uses, among which treatment of diabetes and hypertension.

**Aim of the study**

This study was conducted in order to confirm the antihypertensive and hypotensive effects of *A. campestris* L. aqueous extract (AcAE) and to explore the underlying mechanism of action of its vasorelaxant effect, besides the acute toxicity. Also, the chemical composition of AcAE was investigated.

**Material and methods**

The chemical content of AcAE was determined by using HPLC and NMR techniques. The antihypertensive effect was assessed indirectly by tail-cuff method on L-NAME induced hypertensive rats, while the hypotensive action was monitored intravenously by invasive method on normotensive rats. The vasorelaxant effect and vascular mechanism of action were studied in the presence of antagonists and blockers on aorta isolated from normotensive rats. On the other side, the acute toxicity was studied by oral feeding of extract to the mice.
**Results**

The global phytochemical profile of AcAE reveals the presence of several polyphenols as main components. *A. campestris* L. infusion was characterized by mono- and dicinnamoyl compounds, with 3,5-dicaffeoylquinic (isochlorogenic A) acid being the main compound, followed by 5-caffeoylquinic (chlorogenic) acid. Vicenin-2 (apigenin 6,8-di-C-glucoside) appeared to be the most abundant compound among flavonoids. The daily treatment with AcAE at 150 mg/Kg/day prevented the installation of hypertension on L-NAME hypertensive rats, and reduced SBP from 172 mmHg up to 144 mmHg. At the dose 40 mg/Kg, AcAE provoked reduction of systolic (SBP), diastolic (DBP) and mean arterial pressure (MAP), without affecting the heart rate. Also, AcAE (10^{-2}-2 mg/ml) relaxed the precontracted aorta by 95.8 ± 1.3%. The denudation and preincubation of aorta with atropine, calmidazolium, L-NAME, hydroxycobalamin, ODQ, 8-RP-Br-PET-cGMP, thapsigargin and verapamil attenuated the vasorelaxant response, while the pre-treatment with 4-AP, TEA, glibenclamide and BaCl₂ did not alter this effect. The oral administration of AcAE (0-6 g/Kg) reveals no mortality or toxicity.

**Conclusions**

Our study proved that AcAE possess an important antihypertensive, hypotensive and vasorelaxant effect, which is mediated via calmodulin-NO-cGC-PKG pathway, and via inhibition of calcium influx through voltage-operated calcium channels and activation of intracellular calcium mobilization into sarcoplasmic reticulum. Therefore, our findings give first evidence about the traditional use of *A. campestris* L. as antihypertensive plant.

**Graphical abstract**
Key words

Artemisia campestris L., aqueous extract, phytochemical analysis, antihypertensive, hypotensive, vasorelaxant.

Chemical compounds studied in this article

Chlorogenic acid (PubChem CID: 1794427); 3,4- Dicaffeoylquinic acid (PubChem CID: 5281780); 3,5- Dicaffeoylquinic acid (PubChem CID: 6474310); 4,5- Dicaffeoylquinic acid (PubChem CID: 6436237); Vicenin-2 (PubChem CID: 442664).
1. Introduction

Hypertension is considered as the main current concern of public health due to its high prevalence and its related risk factors. In Africa, the global prevalence attained its maximum by the year 2000 and was estimated by 30.8%, with 33.3% as prevalence average in Northern Africa (Adeloye and Basquill, 2014). In Morocco, the prevalence of this disease was about 33.6% (Tazi et al., 2003), while the frequency of hypertension in Eastern Morocco was accounted for 31.7% (Ziyyat et al., 2014). Even though, the antihypertensive drugs consumption among the Moroccan hypertensive population remains very low for their needs (Berrada El Azizi et al., 2012), which lead to the utilization of traditional herbal medicine as an alternative to treat high blood pressure.

According to ethnomedicinal surveys conducted in four regions of Morocco, 67.5% to 80% of patients use medicinal plants to treat hypertension (Eddouks et al., 2002; Jouad et al., 2001; Tahraoui et al., 2007; Ziyyat et al., 1997). *Artemisia campestris* L. (Asteraceae) is an Eastern Morocco medicinal plant (Fakchich and Elachouri, 2014), that has been botanically identified and characterized based on its essential oil chemotyping (Dib et al., 2017a). This plant is commonly used as antihypertensive (Boudjelal et al., 2013) besides to other common uses like antidiabetic (Bnouham et al., 2002; Boudjelal et al., 2013) diuretic (Benchelah et al., 2004; Ferchichi et al., 2006), emmenagogue (Benchelah et al., 2004; Hammiche and Maiza, 2006; Popović et al., 2012), against digestive (Djidel et al., 2009; Fakchich and Elachouri, 2014; Hammiche and Maiza, 2006; Leporatti and Ghedira, 2009) and cutaneous problems (Benítez et al., 2010; El Hassani et al., 2013), as febrifuge (Guarino et al., 2008), anthelmintic (Hammiche and Maiza, 2006; Popović et al., 2012). The overall of traditional uses and
pharmacological studies of this plant were detailed in a review published by our team (Dib et al., 2016).

According to Ben-Nasr et al. (2014a), it has been evidenced that the water extract of *A. campestris* decreased significantly the diastolic pressure and heart rate in both smoker and non-smoker men, but the systolic pressure did not significantly change. The same author performed experiments on envenomed pregnant and non-pregnant rats with hypertensive phase induced by the venom, and proved that the pre-treatment with the aqueous decoction of *A. campestris* leaves exhibited a preventive antihypertensive effect, and abolished the venom induced hypertensive shock (Ben Nasr et al., 2014b). Recently, we have showed that the essential oil of *A. campestris* L. exhibited a powerful vasorelaxant effect, which was endothelium-independent, and mediated via calcium channels (Dib et al 2017b). In this perspective, this study was carried out with the objective to confirm the antihypertensive action of *A. campestris* L. aqueous extract (AcAE), on L-NAME-induced hypertensive rats. The effect of AcAE on normal blood pressure rats was also explored, and its vasorelaxant effect was studied, with an emphasis to the vascular mechanism of action. Finally, the phytochemical composition of AcAE was characterized with the aim to give a chemical fingerprinting of this plant according to its occurrence in Oriental Morocco.

2. Material and methods

2.1. Plant material

Aerial part of *A. campestris* L. was collected in 2014 at flowering stage in a desert area situated between Tendrara and Figuig (South-Eastern Morocco), called chott Tiggri (32°49′48″ N, 1°39′36″ w). The plant material was identified by Pr. Atika Mihamou
botanist from biology department, and a voucher specimen was deposited in the Herbarium of Faculty of Sciences, University Mohamed First (Oujda, Morocco) under the reference number (HUMPOM-151). The name of the plant was checked and confirmed according the official website www.theplantlist.org.

2.2. Preparation of aqueous extract

A quantity of 250g of A. campestris L. aerial part was infused in boiled distilled water during 4 hours. Then, the extract (AcAE) was filtered and the pooled extract was evaporated to dryness in a rotary evaporator. The yield extract was about 8.37%. The extract was stored at -20°C until use.

2.3. Chemicals and drugs

The following drugs and solvents were used in this study: (±)-verapamil hydrochloride (Sigma Aldrich, China), (R)-(−)-phenylephrine hydrochloride [Phe] (Sigma Aldrich, Germany), 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one [ODQ] (Cayman Chemical, USA) 3,5-Dicaffeoylquinic acid (Chromadex, USA), 3,4-Dicaffeoylquinic acid (Chromadex, USA), 4,5-Dicaffeoylquinic acid (Chromadex, USA)4-aminopyridine [4-AP] (Alfa Aesar, Germany), atropine (Sigma Aldrich, China), barium chloride dehydrate [BaCl2] (AnalaR Normapur - VWR International, Belgium), calcium chloride dehydrate [CaCl2, 2H2O] (Scharlau chemie, Spain), calmidazolium chloride (Sigma Aldrich, USA), carbamylcholine chloride [carbachol, CCH] (Sigma Aldrich, USA), chlorogenic acid (Sigma Aldrich, China), D(+) -glucose anhydrous (Sigma Aldrich_Riedel-de Haen, Germany), Enalapril maleate [Renitec®20mg] (Afric-Phar, Morocco), glybenclamide (Sigma Aldrich, USA), hydroxocobalamin hydrochloride (Fluka, USA), heparin sodium salt (Sigma Aldrich, united kingdom), indomethacin (Sigma Aldrich-Fluka, Italy),
magnesium sulfate [MgSO4] (Sigma Aldrich, Germany), Nω-Nitro-L-arginine methyl ester hydrochloride [L-NAME] (Sigma Aldrich, Switzerland), potassium di-hydrogen phosphate [KH2PO4] (Panreac, Spain), Rp-8-bromo-β-phenyl-1,N2-ethenoguanosine3′,5′-cyclicmonophosphorothioate sodium salt [Rp-8-Br-PET-cGMP] (Sigma Aldrich, Germany), sodium chloride [NaCl] (Sigma Aldrich_Riedel-de Haen, Denmark), sodium hydrogen carbonate [NaHCO3] (Farco chemical, Puerto Rico), sodium nitroprusside [SNP] (Farco chemical, Puerto Rico), sodium pentobarbital (Ceva Santé Animale, France), potassium chloride [KCl] (Sigma Aldrich_Riedel-de Haen, Germany), tetraethyl ammonium chloride hydrate [TEA] (Sigma Aldrich, USA), thapsigargin (Sigma Aldrich, Israel). The solvents utilized were: acetonitrile (Merck, Germany), diethyl ether (Sigma Aldrich, Germany), dimethyl sulfoxide [DMSO] (Sigma Aldrich_Riedel-de Haen, Germany), trifluoroacetic acid [TFA] (Merck, Germany). All chemicals and solvents used were analytical grade. The stock solutions of ODQ, thapsigargin and Rp-8-Br-PET-cGMP were prepared in DMSO whereas indomethacin was prepared in 5% (w/v) sodium bicarbonate solution. All other drugs were dissolved in distilled water.

2.4. **High performance Liquid Chromatography analysis (HPLC/UV-VIS-DAD)**

A sample of 10 mg/ml of AcAE was prepared in methanol and filtered through Chromafil® Pet -45/25 Macherey-Nagel (Germany) 0.45 µm filters. The analysis was carried out on an Agilent 1100 HPLC coupled with a DAD (Diode-Array Detector). A volume of 10 µl of the sample was injected on hypersil ODS column (5 µm, 250 x 4.6 mm) and the analysis was operated at 25 ºC. The mobile phase was constituted of: TFA 0.05 % in water (A), (pH=2.2) and acetonitrile (B). the sample was eluted at flow rate of
1 ml/min and with a linear gradient as follows: 100% (A) and 0% (B) at 0 min, 97% A and 3% (B) at 1 min, 60% A and 40% (B) at 45 min, 60% A and 40% (B) at 55 min, 40% A and 60% (B) at 56 min, 40% A and 60% (B) at 66 min and 100% (A) and 0% (B) at 67 min. The obtained peaks were recorded using UV absorbance at 340 nm, and identified by comparing their retention time and UV spectra to those of standards from an internal database. The identified peaks were numbered 1 to 5 on the chromatogram (Fig. 1).

Identification of peak 2

The peak 2 was identified after carrying out a preparative HPLC (Varian). A concentration of 1g/10ml of AcAE was prepared in methanol, then, filtered through Acrodisc PSF GXF/GHP 0.45 nm filter. This solution was injected and eluted through Lichrospher 100 RP 18 column Merck® (250 x 25 mm, 12 µm), by using a mobile phase consisting of TFA 0.05% (A) and acetonitrile (B). A gradient elution was applied: 100% (A) at 0 min, 60% (A) at 30 min, 40% (A) at 40 min, 20% (A) at 45 min and 0% A at 55 min. Flow rate was 30 ml/min. Detection was performed at 340 nm and time of collect is 0.20 min. The isolated peak (2) was re-analysed by LC/DAD, and identified by Mass Spectrometry and NMR.

Mass spectra were set to negative ion mode. Experiments were performed with a 9.4 tesla Apex-Qe FTICR mass spectrometer (Bruker Daltonics, Billerica, MA). NMR spectra were recorded in DMSO-d6 on a Bruker 500MHz NMR AVI spectrometer equipped with a cryoprobe operating at 500MHz for 1h and 125.7 MHz for 13C, with TMS as an internal reference.

2.5. Experimental animals
Wistar rats and albino mice were provided from the local colonies of department of Biology (Faculty of Sciences-Oujda, Morocco), they were maintained in standard conditions, with a photoperiod of 12 hours light and dark, at 24±2°C, and they were allowed to free access of water and food. All animals were cared for in compliance with the internationally accepted Guide for the care and use of laboratory animals, published by the US National Institutes of Health (NIH Publication No. 85-23, Revised in 1985).

2.6. Acute toxicity test

The acute toxicity of AcAE was carried out on mice of either sex weighing between 23 and 43 g. Animals were divided into five groups of six mice each. The doses 1, 2, 4 and 6 g/kg of AcAE were orally administered to the mice, while the control group was fed with tap water. The signs of toxicity or mortality were observed for the next 4 hours, then for the 48 hours and after the two weeks succeeding the administration of AcAE.

2.7. Hypotensive effect on anesthetized rats

Rats were anesthetized by an intraperitoneal injection of sodium pentobarbital (50 mg/kg body weight) and kept at 37°C during the experiment. Catheters filled with heparin-saline solution (200 IU/ml) were inserted in the femoral vein for drug administration and in the femoral artery for arterial blood pressure recording by using a pressure transducer BP-T (EMKA Technologies, France). The systolic (SBP), diastolic (DBP), mean arterial pressure (MAP) and heart rate (HR) were visualized and analysed by using an acquisition card “National Instrument” and software Labview 6.1. The control values of MBP and HR were recorded just after 30 minutes of stabilisation. then, the baroreflex response of the animal was tested by assessing changes in MBP
and HR after an intravenous (i.v.) injection of bolus (25 µl/100 g of BW) of phenylephrine (PHE, 1.5 µg/kg) and sodium nitroprusside (SNP, 10 µg/kg). After 10 minutes, the baseline values of MPB and HR were recorded, again, before (control) and after injection of AcAE (1, 2.5, 5, 10, 20, 30, 40 mg/kg). The injections were spaced by a time interval of 10 minutes, after stabilisation of the signal.

2.8. Antihypertensive effect on L-NAME hypertensive rats.

Male Wistar rats (N=39) weighing 180-320g were randomly divided into five groups; the control group received tap water (n=5), L-NAME group (n=6) received L-NAME (32 mg/Kg/day), L-NAME + Enalapril (n=7) was co-treated with L-NAME 32 mg/Kg/day and Enalapril 15 mg/Kg/day, while, L-NAME + AcAE 50 (n=7) and L-NAME + AcAE 150 (n=7) received co-consequently L-NAME (32 mg/Kg/day) and respectively the doses 50 mg/Kg/day and 150 mg/Kg/day of AcAE. All treatments were administered daily and orally at volume of 1ml/100g during 4 weeks. The SBP was indirectly measured at the beginning of the treatment and weekly throughout the treatment period, using the non-invasive tail cuff method. The rats were maintained on a holder restrained to get immobilised and placed at a heating table, kept approximately at 37°C for 15 minutes until they got stabilised and to ensure the blood flow on the caudal artery. The transducer placed around the tail and related to an inflation-deflation system permitted the detection of systolic blood pressure signal on plethysmograph apparatus (Innovators in Instrumentation, Landings, USA).

2.9. Vasorelaxant effect on aorta isolated from normotensive rats

Wistar rats weighing 200-300g were used. Rats were anesthetized with sodium pentobarbital (0.1ml/100g body weight). The thoracic aorta was quickly and gently
removed, cleaned of adherent connective tissue and cut into rings (3-4 mm in length). Rings were gently introduced between two stainless-steel hooks and placed in organ chamber (Emka technologies, France) containing 11 ml of Krebs solution gassed with 95% O₂ and 5% CO₂ and maintained at 37 °C and pH 7.4. One hook was connected to an isometric force transducer (Emka technologies, France) and a tension of 1g was applied to the vessels then they were allowed to stabilize for 30 minutes. The composition of Krebs solution was as follow (mmol/L): NaCl 119, KCl 4.7, CaCl₂ 2.6, MgSO₄ 1.2, KH₂PO₄ 1.2, NaHCO₃ 25, and Glucose 11. Endothelial integrity was monitored by the percentage of relaxation evoked by carbachol (10⁻⁴ M) after a steady contraction was reached with phenylephrine (10⁻⁶ M). Rings with carbachol-induced relaxation less than 50% were discarded.

2.9.1. Vasorelaxant effect of AcAE on intact and denuded precontracted aorta, and in the presence of Atropine and Calmidazolium

In endothelium-intact aorta (n = 6), steady tension was evoked by phenylephrine (1 µM), then, AcAE (0.1–100 µg/ml) was cumulatively added to the Krebs solution. To verify if the relaxant effect of AcAE was mediated via the endothelium, denuded rings (n=6) were obtained by gentle rubbing of the lumen of aorta with a plier curved end, and the denudation was verified by the absence of any degree of relaxation caused by carbachol (10⁻⁴ M), then, AcAE (0.1–100 µg/ml) was cumulatively added. In another set of experiments, endothelium-intact rings were pre-incubated with the muscarinic receptor antagonist atropine (1 µM; n=6) and Ca²⁺-Calmodulin binding to NOS blocker calmidazolium chloride (10⁻³ µM; n=6) for 20 minutes prior the contraction with phenylephrine (10⁻⁶ M), then, the cumulative concentration–response curves of AcAE
were constructed and compared with those obtained with untreated rings.

2.9.2. Vasorelaxant effect of AcAE in the presence of L-NAME, Hydroxycobalamin, ODQ and 8-RP-Br-PET-cGMP

Endothelium-intact rings were pre-incubated with the NO synthase inhibitor, Nω-Nitro-L-arginine methyl ester (L-NAME; 10⁻⁴ M; n = 6), the NO scavenger, hydroxocobalamin (3.10⁻⁵ M; n = 6), the guanylyl cyclase inhibitor, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 10⁻⁵M; n = 6), and the competitive cGMP-dependent protein kinase G (PKG) inhibitor, Rp-8-Br-PET-cGMP (3.10⁻⁶ M; n = 6) for 20 minutes prior the contraction with phenylephrine (10⁻⁶ M), then, the cumulative concentration–response curves of AcAE were constructed and compared with those obtained with untreated rings.

2.9.3. Vasorelaxant effect of AcAE in the presence of potassium channels blockers, either TEA, or 4-AP, or BaCl₂, or Glibenclamide

Endothelium-intact rings were incubated with the Ca²⁺-activated potassium channels, tetraethyl ammonium (TEA; 10⁻²M; n=6), the selective voltage-activated potassium channel (Kᵥ) blocker, 4-aminopyridine (4-AP; 10⁻⁴M; n=6), the selective inwardly-rectifying potassium channel blocker, barium chloride (BaCl₂; 10⁻⁴M; n=6), and the selective ATP-sensitive potassium channel blocker, glibenclamide (10⁻⁵M; n=6) for 20 minutes prior to contraction with phenylephrine (10⁻⁶M); then, the cumulative concentration–response curves of AcAE were constructed and compared with those obtained with untreated rings.

2.9.4. Vasorelaxant effect of AcAE in the presence of either Indomethacin, or Thapsigargin, or Verapamil
To determine if prostanoid (PGI$_2$) was responsible of the relaxant effect of AcAE, endothelium-intact rings were pre-incubated with the non-selective cyclooxygenase inhibitor, indomethacin (10$^{-5}$M; n=6), and to explore the role of calcium channels in the vasorelaxant effect, endothelium-intact rings were incubated with the Ca$^{2+}$-channel type VOC, verapamil (10$^{-5}$ M; n=6) and the endoplasmic reticulum Ca$^{2+}$-ATP$_{ase}$ (SERCA) inhibitor, thapsigargin (10$^{-7}$ M; n=6) for 20 minutes prior to contraction with phenylephrine (10$^{-6}$ M), then, the cumulative concentration–response curves of AcAE were constructed and compared to those obtained with untreated rings.

2.10. Statistical analysis

The data were expressed as the mean ± standard error of mean (SEM). The results were analysed using one-way and two-way analysis of variance (ANOVA), followed by Bonferroni’s as a post-test. A value of $p < 0.05$ was considered significant. The chemical structures have been drawn by using the freeware version of the software ACD/ChemSketch (Freeware) 14.01.

3. Results

3.1. High performance liquid chromatography analysis (HPLC/UV-VIS-DAD)

The HPLC analysis of AcAE reveals a quite simple chromatographic profile (see Fig. 1), with three major peaks: chlorogenic acid (peak 1), vicenin-2 (peak 2) and 3,5-Dicaffeoylquinic acid (peak4). The peaks 1 to 5 were identified by means of their UV/vis spectra and their relative retention times, and literature data (Scifinder, 2016) corroborated these assignments. Co-injection with reference standards confirmed our hypothesis for the caffeoylquinic acids (chlorogenic and the three isochlorogenic acids).
Fig. 1. LC chromatogram of *A. campestris* L. aqueous extract (AcAE) visualized at the wave length of 340 nm. Peaks were detected using DAD detector. Peak (1): chlorogenic acid, peak (2): vicenin-2, peak (3): 3,4-dicaffeoylquinic acid (isochlogenic acid C), peak (4): 3,5-dicaffeoylquinic acid (isochlogenic acid A), peak (5): 4,5-dicaffeoylquinic acid (isochlogenic acid B).

Vicenin-2 (apigenin 6, 8-di-C-glucoside) was identified by spectroscopic analysis (UV, MS and NMR) and comparison with literature data (Sawabe et al., 1989; Scifinder, 2016). Chemical structures of identified compounds are represented in Fig. 2.

3.2. **Acute toxicity test**

The single oral dose of 1, 2, 4 and 6 g/Kg of AcAE administered to the mice did not produce any symptoms of toxicity or mortality during the 2 weeks observations.

3.3. **Hypotensive effect on anesthetized rats**

AcAE at doses 1, 2.5, 5, 10, 20, 30 and 40 mg/Kg reduced the systolic blood pressure (SBP) respectively, by 8.9±0.7, 8.1±2.4, 14.4±3.4, 21.3±2, 28.4±5.2, 32.5±2.7, 33.2±4 %, and the diastolic blood pressure (DBP) respectively, by 15.6±1.4, 8.4±2.5, 19.6±3.1, 28.1±3.2, 38.0±6.7 and 46.9±3.6.
Fig. 2. Chemical structures of compounds identified in *A. campestris* L. aqueous extract (AcAE).

Similarly, the mean arterial pressure (MAP) was lowered by treatment with AcAE; the reduction of MAP was: 7.6±1.3, 7.7±2.4, 20.2±4.6, 23.3±2.8, 32.1±6.3, 37.0±3.2, 41.1±4.7 %, respectively at doses 1, 2.5, 5, 10, 20, 30 and 40 mg/Kg. Heart rate were not significantly affected by treatment with AcAE (Fig.3).
Fig. 3. Effect of intravenous injection of *A. campestris* L. (AcAE) on (A) systolic blood pressure (SBP), (B) diastolic blood pressure (DBP), (C) mean arterial pressure (MAP) and (D) heart rate (HR) in anesthetized rats. Values are mean ± SEM, n=5. Two way ANOVA followed by Bonferroni’s post-test; * p < 0.05 and *** p <0.001 vs control (before treatment), NS: not significant. Original tracings showing the effect of intravenous injection of cumulative doses of *A. campestris* L. aqueous extract (AcAE) on (E) mean arterial pressure and (F) heart rate.
3.4 Antihypertensive effect

As shown in Fig. 4, at the beginning of the experiment, the baseline SBP values did not differ between the experimental groups. Daily administration of L-NAME (32 mg/Kg/j) induced a progressive increase in systolic blood pressure of L-NAME group from 123.3±1.05 mmHg and reached 172.5±2.8 mmHg at the end of treatment.

Fig. 4. Effect of four-weeks treatment on systolic blood pressure (SBP) of rats fed with L-NAME (L-NAME group), Enalapril (L-NAME+Enalapril group), and A. campestris L. aqueous extract at 50 mg/Kg/day (L-NAME+AcAE 50 group) and at 150 mg/Kg/day (L-NAME+AcAE150 group). Data are mean ± S.E.M (n=5-7 rats per group). Two way ANOVA followed by Bonferroni’s post-test; b: p < 0.01; c: p < 0.001 vs. control group; β: p < 0.01; γ: p < 0.001 vs. L-NAME group.

This increase was significant from the first week until the end of experiment compared to control group (122.6 ± 1.9 mmHg; p < 0.001). At the end of the fourth week, the SBP of the rats in the L-NAME+Enalapril group (139.3 ± 2.5 mmHg; p < 0.001), L-NAME +
AcAE 50 group (146.4 ± 1.6 mmHg; \( p < 0.001 \)) and L-NAME + AcAE 150 group (144.2 ± 1.5 mmHg; \( p < 0.001 \)) was significantly lower than that of L-NAME group.

3.5. **Vasorelaxant effect on aorta isolated from normotensive rats**

3.5.1. **Vasorelaxant effect of AcAE on intact and denuded precontracted aorta, and in the presence of Atropine and Calmidazolium**

AcAE \( (10^{-2} - 2 \text{ mg/ml}) \) induced 95.8 ±1.8% (n=6) of relaxation of aorta contracted by phenylephrine \( (10^{-6} \text{ M}) \). The vasorelaxation produced by AcAE was markedly attenuated after denudation of aorta (26.9% ±2.1; \( p<0.001 \)). Also, the vasodilator effect was significantly reduced when aorta was pretreated with atropine, the muscarinic receptor inhibitor (69.9% ±7.1; \( p<0.001 \)) and with calmidazolium, the calcium-calmodulin binding to NO synthase blocker (54.2% ±14.8; \( p<0.001 \)) (Fig. 5).

3.5.2. **Vasorelaxant effect of AcAE in the presence of L-NAME, Hydroxycobalamin, ODQ and 8-RP-Br-PET-cGMP**

Vasorelaxant effect produced by AcAE \( (10^{-2} - 2 \text{ mg/ml}) \) was decreased after the pre-incubation of aorta with L-NAME, NO synthase inhibitor (35.1 ±5.1%; \( p<0.001 \)), hydroxocobalamin, NO scavenger (38.9 ± 7.1%; \( p<0.001 \)), ODQ, the guanylyl cyclase inhibitor (67.4 ±3.4%; \( p<0.001 \)) and Rp-8-Br-PET-cGMP, the competitive cGMP-dependent protein kinase G (PKG) inhibitor (69.1 ±8.2%; \( p<0.001 \)) (Fig. 6).
Fig.5. (I) Concentration–response curves of the vasorelaxant effect of *A. campestris* L. aqueous extract (AcAE) on aorta isolated from normotensive rats and pre-contracted with phenylephrine $10^{-6}$ M (●), on denuded aorta (■), and in the presence of Atropine (▲) and Calmidazolium (▼). Values are mean ± SEM, n=5-6. Two way ANOVA followed by Bonferroni’s post-test; ** p<0.01 and *** p < 0.001 vs control. (II) Original tracing showing the effect of carbachol $10^{-4}$ M on precontracte aorta with phenylephrine $10^{-6}$ M (endothelium integrity control) (A), and the vasorelaxant effect of *A. campestris* L. aqueous extract (AcAE) on isolated aorta pre-contracted with phenylephrine $10^{-6}$ M (B), on denuded aorta (C), and in the presence of atropine (D) and calmodizalium (E).
**Fig. 6.** (I) Concentration–response curves of the vasorelaxant effect of *A. campestris* L. aqueous extract (AcAE) on aorta isolated from normotensive rats and pre-contracted with phenylephrine $10^{-6}$ M (●), and in the presence of L-NAME (■), Hydroxocobalamin (▲), ODQ (▼) and 8-RP-Br-PET-cGMP (◆). Values are mean ± SEM, n=5-6. Two way ANOVA followed by Bonferroni’s post-test; *p < 0.05 and *** p < 0.001 vs control. (II) Original tracing showing the effect of charbachol $10^{-4}$ M on precontracte aorta with phenylephrine $10^{-6}$ M (endothelium integrity control) (A), and the vasorelaxant effect of *A. campestris* L. aqueous extract (AcAE) on isolated aorta pre-contracted with phenylephrine $10^{-6}$ M (B), in the presence of L-NAME (C), hydroxocobalamine (D), ODQ (E), and 8-RP-Br-PET-cGMP (F).
3.5.3. **Vasorelaxant effect of AcAE in the presence of Indomethacin, Thapsigargin, Verapamil**

The vasorelaxant effect of AcAE ($10^{-2} - 2$ mg/ml) was inhibited after exposing aorta to the blocker of VOC-calcium channels, verapamil ($36.2 \pm 3.3\%$; $p<0.001$) and to the inhibitor of endoplasmic reticulum calcium-ATPase, thapsigargin ($30.7 \pm 3.8\%$; $p<0.001$). However, the inhibition of cyclooxygenase, by pretreatment with indomethacin did not alter the vasorelaxant effect evoked by AcAE ($88.3 \pm 4.3\%$; $p>0.05$) (Fig. 7).

3.5.4. **Vasorelaxant effect of AcAE in the presence of potassium channels blockers, TEA, 4-AP, BaCl₂ and Glibenclamide**

The relaxation triggered by AcAE ($10^{-2}-2$ mg/ml) was not influenced after pretreatment of aorta with various potassium channels blockers such as TEA ($93.1 \pm 5.6\%$; $p> 0.05$), 4-AP ($90.8 \pm 2.4\%; p> 0.05$), BaCl₂ ($87.7 \pm 4.4\%; p> 0.05$) and glibenclamide ($81.7 \pm 7.4\%$; $p> 0.05$) (Fig.8).

4. **Discussion**

The present work investigated the phytochemical composition of the aqueous extract of *A. campestris* L. (AcAE) from Oriental Morocco, and showed no acute toxicity when tested on mice. Moreover, the hypotensive effect of AcAE intravenous injection to normotensive rats and antihypertensive effect of oral administration of the extract to L-NAME induced hypertensive rats during four weeks have been highlighted; also, the vasorelaxant effect mechanism of action was explored on isolated rat aorta and pointed out that AcAE act through both endothelium dependent and independent vasorelaxant pathways.
Fig. 7. (I) Concentration–response curves of the vasorelaxant effect of *A. campestris* L. aqueous extract (AcAE) on aorta isolated from normtensive rats and pre-contracted with phenylephrine $10^{-6}$ M (●) and in the presence of Thapsigargin (■), Verapamil (▲) and Indomethacin (▼). Values are mean ± SEM, n=6. Two-way ANOVA followed by Bonferroni’s post-test; *** p < 0.001 vs control. (II) Original tracing showing the effect of carbachol $10^{-4}$ M on precontracte aorta with phenylephrine $10^{-6}$ M (endothelium integrity control) (A), and the vasorelaxant effect of *A. campestris* L. aqueous extract (AcAE) on isolated aorta pre-contracted with phenylephrine $10^{-6}$ M (B), in the presence of thapsigargin (C), verapamil(D), and indomethacin (E).
The HPLC analysis confirmed the presence of chlorogenic acid and three isochlorogenic acids: 3,4-dicaffeoylquinic acid (isochlorogenic acid B), 3,5-dicaffeoylquinic acid (isochlorogenic acid A) and 4,5-dicaffeoylquinic acid (isochlorogenic acid C). These findings are in congruence with a previous work carried out by Riedel et al. (2010), that found the same HPLC profile of cell culture of A. campestris L. occurring in Germany. Additional studies are available, showing the presence of chlorogenic acid in the phenolic-rich extract (Djeridane et al., 2007) and in the aqueous extract (Sebai et al., 2014) of A. campestris L.

The isochlorogenic acids were also detected in the water fraction and aqueous extract of A. campestris L. from Tunisia (Megdiche-Ksouri et al., 2015; Sebai et al., 2014). Data of other authors reported the occurrence of flavonoids such as chrysin, apigenin, luteolin, kaempferol, quercetin, myricetin and their derivatives (Akkari et al., 2014; De Pascual Teresa et al., 1986; De Pascual Teresa et al., 1984; Ferchichi et al., 2006; Hurabielle et al., 1982; Karabegović et al., 2011; Megdiche-Ksouri et al., 2015; Rauter et al., 1989; Sebai et al., 2014; Valant-Vetschera et al., 2003; Vasconcelos et al., 1998). Nevertheless, our study represents the first evidence about the existence of the glycoside flavonoid vicenin 2 as the main flavonoid present in the aqueous extract of A. campestris L. (AcAE) from Eastern Morocco.

In a preliminary step to ensure the safety of AcAE, the extract was tested for its oral acute toxicity. Consequently, the LD$_{50}$ was greater than 6 g/Kg, which seems to be much higher than that of the aqueous extract of Tunisian A. campestris L. orally administered to the mice (LD$_{50}$ > 3.2 g/Kg) (Sebai et al., 2014), and injected intraperitoneally (LD$_{50}$= 2.5 g/Kg) (Sefi et al., 2010).
Fig. 8. (I) Concentration–response curves of the vasorelaxant effect of *A. campestris* L. aqueous extract (AcAE) on aorta isolated from normotensive rats and pre-contracted with phenylephrine $10^{-6}$ M (●), and in the presence of TEA ( ■), 4-AP (▲), BaCl$_2$ (▼) and Glibenclamide (◆). Values are mean ± SEM, n=6. (II) Original tracing showing the effect of carbachol $10^{-4}$ M on precontracte aorta with phenylephrine $10^{-6}$ M (endothelium integrity control) (A), and the vasorelaxant effect of *A. campestris* L. aqueous extract (AcAE) on isolated aorta pre-contracted with phenylephrine $10^{-6}$ M (B), in the presence of TEA (C), 4-AP (D), BaCl$_2$ (E), and glibenclamide (F).
The extract also revealed a positive safety profile explained by the absence of any behavioural perturbations during the 2 weeks following the administration.

In our experiment, we proved the potential activity of *A. campestris* L. at lowering the blood pressure levels by testing the effect of AcAE on normotensive and hypertensive rats. Accordingly, the extract induced 41.1% drop of MAP of normal rats (with, 33.2% for SBP and 46.9% for DBP), at the dose of 40 mg/Kg, while the heart rate was not affected. The absence of any effect on the heart rate may lead to speculate that the hypotensive effect of AcAE is mainly mediated via a vascular pathway.

Besides, an antihypertensive action on L-NAME induced hypertensive rats was evidenced, and the results showed that AcAE at doses 50 and 150 mg/Kg/day given concomitantly to the NO synthase inhibitor (L-NAME) exerted about the same degree of preventive action against the rise of SBP and which was comparable to the effect of reference antihypertensive drug (enalapril; angiotensin-converting enzyme (ACE) inhibitor). These data may suggest that the antihypertensive effect of AcAE is probably attributed to its ability to inhibit the impairment of NO signalling associated to L-NAME treatment (Paulis et al., 2008). In the light of these findings, it is noteworthy to point out that it has been shown in a previous study that aqueous extract of *A. campestris* leaves, prevents the induced hypertensive phase induced by the scorpion venom in rats, probably through adrenergic pathway (Ben Nasr et al., 2014b).

The antihypertensive mechanism of action of AcAE was explored on vascular signalling pathways. Indeed, AcAE provoked a total relaxation of contracted aorta isolated from normotensive rats, which seems to be endothelium dependent, since the relaxant effect disappeared after the denudation process. Given the major importance of
endothelium in the regulation of vascular tone by releasing vasodilator factors such as nitric oxide (NO), prostacyclin (PGI₂) and endothelium-derived hyperpolarizing factor (EDHF) (Sandoo et al., 2010), the participation of endothelium mediators in the obtained vasorelaxant response was investigated. It is well known that the muscarinic vasorelaxation is mainly mediated via NO production in endothelial cells, which is triggered by the activation of endothelial nitric oxide synthase (eNOS), induced by Ca²⁺-calmodulin complex (Furchgott and Zawadzki, 1980; Harvey, 2012). Our results showed that the pre-treatment of aorta with atropine, a selective muscarinic receptor antagonist, and with calmidazolium, a Ca²⁺-calmodulin binding to NOS blocker, significantly reduced AcAE-induced vasorelaxation, which may suggest that the aqueous extract act via muscarinic receptor and interfere with the site of action of Ca²⁺-calmodulin complex in the vascular endothelium. More interestingly, NO was identified as the pilot modulator of vascular tone; once synthetized within the cytosol of endothelial cell by NOS, NO diffuses into adjacent vascular smooth muscle cells (VSMC) and bind to soluble guanylyl cyclase (sGC) which mediate the vasorelaxation action (Walford and Loscalzo, 2003). In this concern, we performed separate experiments, in which we preincubated aorta with L-NAME (NOS inhibitor) and with hydroxycobalamin (NO scavenger). In the presence of both blockers, AcAE induced-vasorelaxation seems to be totally blunted, indicating the involvement of NO in the observed effect.

The cyclic GMP-PKG signalling within the VSMC represents the final cascade of vasorelaxation initiated by NO production (Furchgott, 1983). Hence, it was reported that NO activates sGC that enhances the conversion of GTP to cGMP. Subsequently,
cGMP activatesPKG that decreases the cytosolic free calcium level through several mechanisms, which finally resulted in the vessel relaxation (Hofmann et al., 2000). This asseveration was proved when vascular relaxation was lost on aorta submitted to ODQ, the inhibitor of sGC, and to Rp-8-Br-PET-cGMPs, the inhibitor of PKG; thing that may lead to postulate about the contribution of sGC and PKG in the vasodilatory effect of AcAE.

The cyclooxygenase (COX) product, prostacyclin (PGI$_2$), is an endogenous mediator of endothelium derived relaxation (Félétou et al., 2011), via activation of cAMP (Parkington et al., 2004). Nevertheless, the participation of prostacyclin in the vasorelaxant effect of AcAE was ruled out, because the relaxation was not affected by the treatment with the COX inhibitor, indomethacin.

The intracellular calcium concentration [$Ca^{2+}$] is an ubiquitous parameter that regulates vascular smooth muscle contractile state. The major [$Ca^{2+}$] is principally linked to the opening of voltage operated calcium (VOC) channels, which are finely controlled by the membrane potential (Ledoux et al., 2006). One the other hand, the re-uptake of intracellular calcium is considered as regulating mechanism of the vascular contractility, and the sarcoplasmic reticulum represents the major storage site of cytosolic calcium; in fact, the sequestration of excessive intracellular calcium occurs via an energy-dependent sarco-endoplasmic reticulum $Ca^{2+}$-ATPase pump (SERCA) (Laporte et al., 2004). Our data reported significant decrease of vasoactivity of AcAE after the incubation with verapamil, the L-type calcium inhibitor, and thapsigargin (inhibitor of the SERCA pump), which indicates that SERCA activation and VOCC channels inhibition account for the vascular dilation produced by the extract.
Otherwise, the opening of potassium channels ($K^+$) triggers an increase in $K^+$ efflux, provoke membrane potential ($E_m$) hyperpolarization and subsequent closure of VOC calcium channels, causing a decrease of intracellular $Ca^{2+}$ mobilization followed by a vasodilation (Ko et al., 2008; Sobey, 2001). Our findings reveal that pretreatment of aorta with potassium channels blockers did not modify the vascular effect of AcAE, which discarded the possible intervention of potassium channels in the vasorelaxant effect.

As mentioned above, A.campestris L. extract (AcAE) exhibited a relevant antihypertensive effect on L-NAME-induced hypertensive rats, where the NO synthesis is assumed to be inhibited. So, one may wonder how AcAE is acting on a model where NOS is completely inhibited by L-NAME whereas its action is mediated mainly through the NO pathway. This effect, controversial and confusing at the first glimpse, can be well justified taking into account that the present treatment is aimed at exploring the preventive antihypertensive effect of AcAE rather than its curative effect, because the extract was administered concomitantly with L-NAME (the selective inhibitor of NOS), and so, the supplementation of AcAE for four weeks tended likely to prevent the presumable action of L-NAME to inhibit NO release by blockade of NOS and to avoid the development of hypertension. It is probable that the co-administration of L-NAME and the extract triggered a competitive action between the two products on NOS activity. Hence, the activator effect of AcAE on NOS seems to be more pronounced and succeeded to reduce the inhibitory effect of L-NAME, and so neutralizing the blockade of NOS. This hypothesis may lead to postulate that the treatment with AcAE is most efficient to prevent, with an earlier way, the NO deficiency, by acting on the vascular
compartment to increase the NO bioavailability leading to the vasorelaxant effect on the favor of the antihypertensive action. With respect to the human projected dose or human equivalent dose (HED), it was calculated according to the method proposed by Reagan-Shaw et al. (2008) and based on comparison of the body surface area of the different animal species. The HED for the aqueous extract of A. campestris L. (AcAE) are 8.1 mg/kg (486.5 mg for a 60 kg person) for the first dose of 50 mg/kg in the rat and 24.3 mg/kg (1.46 g of AcAE for a 60 kg person) for the second dose of 150 mg/kg in rats. Since the antihypertensive effect of the aqueous extract of A. campestris L. (AcAE) at the dose of 50 mg/kg was comparable to that of the standard drug (Enalapril) and taking into account the extraction yield (8.7%), the effective dose to be consumed by humans corresponds to 93.1 mg of the plant /kg of weight /day. For an adult person of 60 kg, the daily necessary quantity is 5.59 g. Compared to infusion bags (which contain about 2 g of plant for one cup of water), this amount corresponds to 3 cups of herbal tea per day. Based on information from three herbalists interviewed in Oujda market, the recommended dose for the traditional use of A. campestris was estimated in a handful of the aerial part (approximately 20 g) in a cup (about 100 ml) of boiled water. The preparation can be consumed three times a day. Using the yield of the extraction found in our study (8.7%), the dose taken would be about 1.74 g of plant / 100 ml for each cup, which is the equivalent of 5.22 g of the net weight of the plant distributed three times a day.

On the basis of these data, it can be concluded that the human dose projected (8.1 mg/kg in humans, equivalent to 50 mg/kg in rats) is quite similar to the dose commonly used in traditional medicine.
Taking into account the antihypertensive effects of chlorogenic acids and mechanisms of improving endothelial function in hypertensive rats (Suzuki et al., 2006; Zhao et al., 2012), and considering the abundance of AcAE on chlorogenic and isochlorogenic acids it can be hypothesized that such compounds are at least partially or even mainly responsible of the antihypertensive and vasorelaxant observed effects. Nevertheless, the effect of vicenin-2 (6,8-di-C-glucosylapigenin) could also play an important role in the effect of AcAE. Indeed, this flavonoid exhibited the strongest hypotensive activity for hypertensive rats among seventy-three glycosides investigated. This activity was not only found with intravenous administration (Sawabe et al., 1989), but also after oral administration. In the latter case, C-glucosyl flavonoids are considered to be not hydrolyzed by the digestive system and hydrochloric acid (Sawabe and Matsubara, 1999). This hypothesis was recently confirmed by the investigations carried on vicenin-2, the active principle of an anti-inflammatory Brazilian medicinal plant (Buqui et al., 2015). Furthermore, vicenin-2 is a constituent of Crataegus monogyna, an old hypotensive medicinal plant used in Europe (Nikolov et al., 1981).

5. Conclusion

The present study gives evidence that A. campestris L. aqueous extract (AcAE) possess potent hypotensive, antihypertensive and vasorelaxant effects. The vasorelaxant effect of AcAE seems to be due to activation of muscarinic receptor and stimulating calmodulin-NO-sGC-PK pathway. An additional mechanism of action of AcAE is mediated via activation of SERCA pump and inhibition of VOCC channels. In relation with the chemical composition of AcAE it appears that the extract is predominantly composed of phenolic compounds (chlorogenic and isochlorogenic acids as well as
vicenin-2) which may be principally involved in the vasodilator effect.

Author’s contributions

I. Dib conducted the animal studies, performed the statistical analysis and wrote the manuscript.

A. Ziyyat is the supervisor of the student Ikram Dib who oversaw the work in its entirety; It obviously discussed and approved all the protocols of pharmacological studies and reviewed and corrected the article several times

A. Assaidi contributed to the achievement of the hypotensive and antihypertensive experiments.

A. Legssyer gives technical directives to perform the tail cuff method for caudal arterial pressure measuring.

M. Tits, L. Angenot, M. Frédéric, and J.-N. Wauters approved the chromatographic technics applied to the analyzed samples, and assisted the analyses of the aqueous extract of *Artemisia campestris* L., and participated in the correction of the manuscript.

H. Mekhfi, M. Bnouham, and M. Aziz helped in the correction of the manuscript.

All the authors read the manuscript and approved the final version.

Acknowledgments

This work was supported by «la Commission Universitaire pour le Développement du CIUF (CIUF-CUD)». We are grateful to Professor Mihamou Atika (Laboratoire de Biologie des Plantes et des Microorganismes, Département de Biologie, Faculté des
We thank Miss. Delphine Etienne (Laboratoire de pharmacognosie, Liège-Belgique) for technical assistance and Mr. Mostafa Bedraoui from our laboratory (Laboratoire de Physiologie, Génétique et Ethnopharmacologie-Faculté des Sciences, Université Mohamed Premier, Oujda) for the reliable care of animals breeding.

References


Megdiche-Ksouri, W., Trabelsi, N., Mkadmini, K., Bourgou, S., Noumi, A., Snoussi, M., Barbria, R., Tebourbi, O., Ksouri, R., 2015. Artemisia campestris phenolic compounds have antioxidant and antimicrobial activity. Industrial Crops and Products 63, 104-113.


Glossary

[Ca^{2+}]: intracellular calcium concentration; 4-AP: 4-aminopyridine; AcAE: Artemisia
campestris L. aqueous extract; BaCl₂: barium chloride; BP-T: blood pressure transducer; cAMP: cyclic adenosine monophosphate; CCH: carbachol; cGMP: cyclic guanosine monophosphate; COX: cyclooxygenase; DAD: diode array detector; DBP: diastolic blood pressure; DMSO: diméthylsulfoxyde; \( E_m \): membrane potentiel; EDHF: endothelium derived hyperpolarizing factor; eNOS: endothelial nitrous oxide synthase; GTP: guanosine triphosphate; HR: heart rate; L-NAME: Nω-nitro-L-arginine methyl ester hydrochloride; LD\(_{50}\): median lethal dose; MAP: mean arterial pressure; NMR: nuclear resonance magnetic; NO: nitrous oxide; NOS: nitrous oxide synthase; ODQ: 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; PGI₂: prostacyclin ; Phe/PHE: phenylephrine; PKG: protein kinase G; Rp-8-Br-PET-cGMPS: Rp-8-bromo-β-phenyl-1,N2-ethenoguanosine 3′,5′-cyclic monophosphorothioate sodium salt; SBP: systolic blood pressure; SERCA: sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase; sGC: soluble guanylyl cyclase; SNP: sodium nitroprusside; TEA: tetraethylammonium; TFA: trifluoroacetic acid; UV: ultraviolet; VOC: voltage-operated channels; VOCC: voltage-operated calcium channels; VSMC: vascular smooth muscle cell.